Insulin Glargine; Lixisenatide Patents

Given below is the list of patents protecting Insulin Glargine; Lixisenatide, along with the drug name that holds that patent and the company name owning that drug.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Insulin Glargine; Lixisenatide's patents.

Latest Legal Activities on Insulin Glargine; Lixisenatide's Patents

Given below is the list recent legal activities going on the following patents of Insulin Glargine; Lixisenatide.

Activity	Date	Patent Number
Critical Events for all Patents
Payment of Maintenance Fee, 8th Year, Large Entity	12 Jun, 2024	US9526764
Payment of Maintenance Fee, 4th Year, Large Entity	20 Apr, 2022	US10117909
Payment of Maintenance Fee, 4th Year, Large Entity	12 Jan, 2022	US10029011
Payment of Maintenance Fee, 4th Year, Large Entity	06 Oct, 2021	US9950039
Payment of Maintenance Fee, 4th Year, Large Entity	11 Jun, 2020	US9526764
Patent Issue Date Used in PTA Calculation Critical	06 Nov, 2018	US10117909
Recordation of Patent Grant Mailed Critical	06 Nov, 2018	US10117909
Issue Notification Mailed Critical	17 Oct, 2018	US10117909
Dispatch to FDC	01 Oct, 2018	US10117909
Application Is Considered Ready for Issue Critical	01 Oct, 2018	US10117909

Insulin Glargine; Lixisenatide's Family Patents

Full family tree

Explore Our Curated Drug Screens